Posts

Showing posts with the label Drug-Resistant Epilepsy (DRE) competitive landscape

Drug-Resistant Epilepsy (DRE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Drug-Resistant Epilepsy (DRE) is associated with neuroinflammatory, autoimmune, and neurodegenerative processes. Immune, pathophysiological, biochemical, and psychological effects are all caused by neuroinflammation. Whether localized or systemic, uncontrolled inflammatory processes result in abnormal neural connections and hyperexcitable neural networks. Anti-epileptic drugs given as monotherapies or in combination fail to achieve sustained seizure freedom because inflammatory mediators affect the endothelium of cerebral vessels, destroy endothelial cell contacts, and induce abnormal angiogenesis, affecting the blood-brain barrier permeability. In 30% to 40% of patients, drug resistance develops, resulting in premature death and brain damage. Drug-resistant epilepsy (DRE) can affect patients of any age recently diagnosed with epilepsy. Patients with DRE have a lower quality of life (QOL), greater medical, social, and financial burden, and a higher mortality rate. ·   ...

Drug-Resistant Epilepsy (DRE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
  Drug-Resistant Epilepsy (DRE) is associated with neuroinflammatory, autoimmune, and neurodegenerative processes. Immune, pathophysiological, biochemical, and psychological effects are all caused by neuroinflammation. Whether localized or systemic, uncontrolled inflammatory processes result in abnormal neural connections and hyperexcitable neural networks. Anti-epileptic drugs given as monotherapies or in combination fail to achieve sustained seizure freedom because inflammatory mediators affect the endothelium of cerebral vessels, destroy endothelial cell contacts, and induce abnormal angiogenesis, affecting the blood-brain barrier permeability. In 30% to 40% of patients, drug resistance develops, resulting in premature death and brain damage. Drug-resistant epilepsy (DRE) can affect patients of any age recently diagnosed with epilepsy. Patients with DRE have a lower quality of life (QOL), greater medical, social, and financial burden, and a higher mortality rate. Epilepsy af...

Drug-Resistant Epilepsy (DRE) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Image
  Drug-Resistant Epilepsy (DRE) is associated with neuroinflammatory, autoimmune, and neurodegenerative processes. Immune, pathophysiological, biochemical, and psychological effects are all caused by neuroinflammation. Whether localized or systemic, uncontrolled inflammatory processes result in abnormal neural connections and hyperexcitable neural networks. Anti-epileptic drugs given as monotherapies or in combination fail to achieve sustained seizure freedom because inflammatory mediators affect the endothelium of cerebral vessels, destroy endothelial cell contacts, and induce abnormal angiogenesis, affecting the blood-brain barrier permeability. In 30% to 40% of patients, drug resistance develops, resulting in premature death and brain damage. Drug-resistant epilepsy (DRE) can affect patients of any age recently diagnosed with epilepsy. Patients with DRE have a lower quality of life (QOL), greater medical, social, and financial burden, and a higher mortality rate. Epilepsy affe...